Dataset from A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy

The primary objective of study Part A is to assess the safety of talacotuzumab (formerly
CSL362) monotherapy and confirm the recommended Phase 2 dose (RP2D) in participants with
acute myeloid leukemia (AML) for whom experimental therapy is appropriate. The primary
objective of study Part B are to assess complete response (CR) rate and overall survival (OS)
in participants with AML who are not eligible for intense induction chemotherapy and who are
randomly assigned to receive decitabine plus talacotuzumab at the RP2D or decitabine alone.